Rhythm Pharmaceuticals, Inc. RYTM Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $217.17M+58.7% | $189.76M+45.8% | $174.33M+54.9% | $156.29M+53.5% | $136.86M+48.9% | ||
| $23M+61.9% | $19.49M+45.8% | $18.48M+44.2% | $16.81M+47.4% | $14.21M+33.0% | ||
| $194.16M+58.3% | $170.27M+45.8% | $155.86M+56.3% | $139.48M+54.3% | $122.65M+51.0% | ||
| 89.4%-0.2pp | 89.7%0.0pp | 89.4%+0.8pp | 89.2%+0.4pp | 89.6%+1.2pp | ||
| $172.09M+17.7% | $167.34M-29.7% | $166.48M-26.6% | $158.38M-28.8% | $146.27M-35.2% | ||
| $219.44M+47.3% | $194.94M+35.1% | $175.59M+26.7% | $158.54M+18.6% | $149.01M+17.1% | ||
| $414.54M+33.9% | $381.77M-3.5% | $360.54M-4.6% | $333.73M-9.2% | $309.49M-14.9% | ||
| -$197.37M-14.3% | -$192.02M+27.7% | -$186.21M+29.9% | -$177.44M+33.2% | -$172.62M+36.5% | ||
| -90.9%+35.2pp | -101.2%+103pp | -106.8%+129pp | -113.5%+147pp | -126.1%+169pp | ||
| $19.76M-4.6% | $20.58M+2.7% | $21.42M+11.8% | $21.92M+28.5% | $20.7M+31.4% | ||
| $15.21M-0.6% | $15.29M+4.0% | $14.72M-1.9% | $14.45M+0.2% | $15.31M+12.9% | ||
| -$4.35M— | -$4.03M— | —— | —— | —— | ||
| -$201.72M-19.7% | -$196.04M+24.7% | -$191.89M+25.7% | -$183.08M+29.1% | -$168.57M+38.3% | ||
| $993K— | $528K— | —— | —— | —— | ||
| -$202.68M-20.1% | -$196.54M+24.6% | -$192.33M+25.7% | -$183.06M+29.4% | -$168.69M+38.4% | ||
| -93.3%+29.9pp | -103.6%+96.7pp | -110.3%+120pp | -117.1%+138pp | -123.3%+175pp | ||
| -$3.13-11.4% | -$3.11+28.5% | -$3.10+28.4% | -$3.01+31.0% | -$2.81+39.3% | ||
| -$3.13-11.4% | -$3.11+28.5% | -$3.10+28.4% | -$3.01+31.0% | -$2.81+39.3% | ||
| 262.9M+6.7% | 258M+6.0% | 254M+5.8% | 249M+5.2% | 246.3M+5.9% | ||
| 262.9M+6.7% | 258M+6.0% | 254M+5.8% | 249M+5.2% | 246.3M+5.9% | ||
| -$206.24M-18.6% | -$202.67M+23.4% | -$198.03M+24.4% | -$190.03M+27.3% | -$173.86M+36.6% | ||
| $5.16M-2.5% | $5.38M+35.5% | $5.39M+105% | $5.34M+310% | $5.29M— | ||
| $15.21M-0.6% | $15.29M+4.0% | $14.72M-1.9% | $14.45M+0.2% | $15.31M+12.9% | ||
| -$30K-151% | $504K+388% | -$27K-104% | $100K+185% | $59K+3.5% | ||
| $514K+624% | -$1.27M-63,700% | -$295K+74.7% | -$1.73M-256% | $71K+131% | ||
| $203K-81.0% | $1.26M-43.6% | $1.53M-38.1% | $2.35M+91.3% | $1.07M+18.1% | ||
| $217.17M+58.7% | $189.76M+45.8% | $174.33M+54.9% | $156.29M+53.5% | $136.86M— | ||
| -$197.37M-14.3% | -$192.02M+27.7% | -$186.21M+29.9% | -$177.44M+33.2% | -$172.62M+36.5% | ||
| —— | —— | —— | —— | —— | ||
| -$197.37M-14.3% | -$192.02M+27.7% | -$186.21M+29.9% | -$177.44M+33.2% | -$172.62M+36.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s revenue?
- Rhythm Pharmaceuticals, Inc. (RYTM) generated $217.2M in revenue over the trailing twelve months, up 58.7% year over year.
- Is Rhythm Pharmaceuticals, Inc. profitable?
- Rhythm Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $202.7M over the trailing twelve months, a -93.3% net margin.
- What are Rhythm Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 89.4% and operating margin is -90.9%, with a -93.3% net margin.
- What is Rhythm Pharmaceuticals, Inc.'s earnings per share?
- Rhythm Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-3.13.
- Where does Rhythm Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Rhythm Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
